Bioventus (NASDAQ:BVS) held its 2026 annual stockholders meeting on June 3, with shareholders voting on two proposals: the election of directors and the ratification of the company’s independent registered public accounting firm.
William A. Hawkins III, chairman of the board of directors and chairman of the meeting, opened the virtual session by welcoming shareholders and introducing members of the board and company officers participating in the webcast. Attendees included Rob Claypoole, Bioventus’ chief executive officer; Mark Singleton, chief financial officer; Tony D’Adamio, general counsel and corporate secretary; and Dave Crawford, vice president of investor relations. Dewayne Southern of Grant Thornton, the company’s independent auditor, was also available to respond to appropriate questions through the meeting’s question-and-answer function.
Shareholders Elect Directors for 2027 Term
D’Adamio said a quorum was present and presented the two proposals recommended by the company. The first proposal was the election of directors for a term expiring at the annual stockholders meeting to be held in 2027, or until each director’s successor is duly elected and qualified.
Based on the preliminary report from Paul Ramirez of Broadridge, who served as inspector of election, the following directors were elected:
- John Bartholdson
- Patrick Beyer
- Robert Claypoole
- Philip Cowdy
- Ajay Dhankhar
- William Hawkins
- Mary Kay Ladone
- Michelle McMurry-Heath
- Guido Neels
- Guy Nohra
- Susan Stalnecker
- Marty Sutter
Grant Thornton Appointment Ratified
The second proposal was the ratification of the Audit Committee’s appointment of Grant Thornton as Bioventus’ independent registered public accounting firm for the year ending Dec. 31, 2026. D’Adamio said the appointment was ratified based on the preliminary vote report.
The polls closed at 10:05 a.m. Eastern Time. D’Adamio said the final tally of votes will be published within four business days in a current report on Form 8-K to be filed with the Securities and Exchange Commission.
No Shareholder Questions Submitted
After the formal meeting was adjourned, Hawkins said the management team would answer questions submitted through the meeting portal. D’Adamio reported that no questions had been received.
Hawkins concluded the meeting by thanking attendees for their interest in Bioventus. The operator then formally closed the webcast.
About Bioventus (NASDAQ:BVS)
Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.
